- Aptinyx (NASDAQ:APTX) -3.5% prices its public offering of 14M common shares at $3.00 per share, for gross proceedsof $42M.
- Underwriters have a 30-day option to purchase up to 2,100,000 additional common shares.
- Closing date is October 26.
- Net proceeds will ne used to advance the development of its novel NMDA receptor modulators, including NYX-2925, NYX-783, and NYX-458, in development for chronic pain, PTSD, and cognitive impairment, respectively, and for working capital and other general corporate purposes.